MR antagonism decreased albuminuria and renal fibrosis in preclinical studies in diabetic rats and mice associated or not with obesity (Cha et al., 2005; Han et al., 2006; Kosugi et al., 2010; Toyonaga et al., 2011; Bhuiyan et al., 2019; Dong et al., 2019; Wang et al., 2019) and clinical studies demonstrated MRA renal benefit in DKD patients (Lindhardt et al., 2016; Sun et al., 2017; Bakris et al., 2020; Wada et al., 2020; Filippatos et al., 2021). Here, NR3C2 is linked to diabetic kidney disease.